Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer

Abstract Background The efficacy of second-line therapy for extensive-stage small cell lung cancer (ES-SCLC) is still limited, with the PFS of 2–3 months. Given the synergistic effect of PD-(L)1 inhibitors and anti-angiogenic agents, their combination represents a novel and promising strategy to rep...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Jian Zhang, Zijie Wu, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Aiqin Gao, Yuping Sun
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-07-01
主題:	Extensive-stage small cell lung cancer (ES-SCLC) PD-(L)1 inhibitors Anlotinib Efficacy Safety
オンライン･アクセス:	https://doi.org/10.1186/s12885-025-14458-5